YOYoshihiro Ohishi

Yoshihiro Ohishi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yoshihiro Ohishi has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Identification of intranuclear inclusions is useful for the cytological diagnosis of ovarian clear cell carcinoma

    by Masaki Naka, Yoshihiro Ohishi, Tsunehisa Kaku, Sumiko Watanabe, Sadafumi Tamiya, Fumihiko Ookubo, Kiyoko Kato, Yoshinao Oda, Setsuo Sugishima


    • 1 June 2012
      • p. 362-6

    [Histological diagnosis of endometrial cancer in biopsy specimen].

    by Tsunehisa Kaku, Sumiko Watanabe, Yoshihiro Ohishi

    • 1 June 2012
      • p. 512-6

    [Pathology of ovarian cancer].

    by Tsunehisa Kaku, Sumiko Watanabe, Yoshihiro Ohishi

    • 1 January 2009
      • Vol. 100  (1) , 13-25

    [Histopathology and molecular biological behaviors in human malignant neoplasms].

    by Masazumi Tsuneyoshi, Takashi Yao, Yoshinao Oda, Sadafumi Tamiya, Shinichi Aishima, Hidetaka Yamamoto, Yoshihiro Ohishi, Minako Hirahashi, Shuichi Kurihara, Kenichi Kohashi

  • Present status of diagnosis of "adenoma malignum" and our activity to improve its interobserver reproducibility

    by Hitoshi Tsuda, Yoshiki Mikami, Tsunehisa Kaku, Futoshi Akiyama, Yuko Sasajima, Tadashi Hasegawa, Yoshihiro Ohishi, Takahiro Kasamatsu

    目的:悪性腺腫 (MDA) と分葉状内頸部腺過形成 (LEGH) に関する病理診断の現状を把握し, 再現性の高い両者の鑑別診断の可能性を検討する.方法:1. 4名の診断者がMDAやLEGHと診断された52例につき各施設の基準で病理診断を行った. 2. 異型のない頸管腺増殖のみの病変をLEGH, このなかに浸潤腺癌の成分が混在する病変をMDAとし, さらにLEGH+上皮内腺癌 (AIS), 通常の腺癌, の4群を設定し, 各組織像を学習後7名の診断者が独立に44例の診断を行った.結果: 1. 診断者間の診断一致の程度はわずかな一致 (κ=0.115) にとどまり, MDAとされた例の死亡率は13~60%と診断者間で大差があった, 2. 診断一致の程度は4群問でかなりの一致 (κ=0.618) に改善し, 非浸潤群 (LEGHとLEGH+AIS), 浸潤群 (MDAと通常の腺癌) 2群間ではほぼ完全な一致 (κ=0.928) を示した. 非浸潤群22例, 浸潤群14例の5生率は各100%, 54%であった.結論:MDAとLEGHの病理診断はいまだ混同があるが, 適切な基準の採用と学習により, 再現性が高く予後と関連する病理鑑別診断が十分可能と考えられた. 標準化や普及, 術前診断の検討が課題と考えられる.

  • Open Access

    ATP‐binding cassette superfamily transporter gene expression in human soft tissue sarcomas

    by Yoshinao Oda, Tsuyoshi Saito, Naomi Tateishi, Yoshihiro Ohishi, Sadafumi Tamiya, Hidetaka Yamamoto, Ryohei Yokoyama, Takeshi Uchiumi, Yukihide Iwamoto, Michihiko Kuwano, et al.

    The phenomenon of multidrug resistance (MDR) in various malignant neoplasms has been reported as being caused by one or multiple expressions of ATP‐binding cassette (ABC) superfamily protein, including P‐glycoprotein/multidrug resistance (MDR) 1 and the MDR protein (MRP) family. However, their expression levels and distribution within soft tissue sarcomas remain controversial. In 86 cases of surgically resected soft tissue sarcoma, intrinsic mRNA levels of MDR1, MRP1, MRP2 and MRP3 were assessed using a quantitative reverse transcriptase‐PCR (RT‐PCR) method. Moreover, immunohistochemical protein expressions of P‐glycoprotein (P‐gp), MRP1, MRP2, MRP3 and p53 protein were evaluated in concordant paraffin‐embedded material. The mRNA expression and immunohistochemical expression of ABC superfamily transporters were compared to clinicopathologic parameters and proliferative activities as evaluated by the MIB‐1‐labeling index (LI). Among the various histologic types, malignant peripheral nerve sheath tumor (MPNST) showed significantly high levels of MDR1 (p=0.017) and MRP3 (p=0.0384) mRNA expression, compared to the other tumor types. When the immunohistochemical method was compared to the RT‐PCR technique to assess ABC transported expression at the protein and mRNA levels, a significantly close relationship was found between the 2 methods (pp=0.041) and high AJCC stage (stages III and IV) (p=0.0365). Furthermore, cases with nuclear expression of p53 revealed significantly higher levels of MDR1 mRNA expression, compared to those with negative immunoreaction for p53 (p=0.0328). Our results suggest that MDR1/P‐gp expression may have an important role to play in tumor progression in the cases of soft tissue sarcoma, and p53 may be one of the active regulators of the MDR1 transcript. In addition, the high levels of both MDR1 and MRP3 mRNA expression in MPNST may help to explain the poor response of this tumor to anticancer‐drugs.


    • 1 December 2002
      • Vol. 8  (12) , 3767-75

    ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma.

    by Yoshihiro Ohishi, Yoshinao Oda, Takeshi Uchiumi, Hiroaki Kobayashi, Toshio Hirakawa, Shingo Miyamoto, Naoko Kinukawa, Hitoo Nakano, Michihiko Kuwano, Masazumi Tsuneyoshi

    The purpose of this study is to attempt to characterize patients with unfavorable clinical outcome by the relative mRNA levels of ABC transporter expression in their tumor samples and to examine whether relative mRNA levels of each of the ABC transporters can be a useful predictor of progression-free survival in advanced ovarian carcinoma. We examined tumor samples taken from 30 patients with primary serous papillary adenocarcinoma of the ovary for the expression of MDR1 and MRP1, MRP2, and MRP3 mRNA by using real-time reverse transcription-PCR, and we evaluated its correlation with clinical outcome. All 30 patients were divided into three groups according to clinical outcome after debulking surgery and platinum-based chemotherapy: 8 patients were classified into the unfavorable group; 11 were classified into the favorable group; and 11 were classified into intermediate group. The relative mRNA levels of MRP1 and MRP3 were significantly different among the three groups, and the mRNA levels of MRP1 and MRP3 in the unfavorable group were significantly higher than those in the favorable group by multiple comparison. The relative mRNA levels of MRP1 expression were significantly correlated with those of MRP3 expression. In the 30 patients with serous papillary adenocarcinoma, univariate and multivariate analysis demonstrated that the high relative mRNA levels of MRP1 expression were significantly correlated with a short period of progression-free survival. In patients with advanced ovarian serous papillary adenocarcinoma, these results suggest that patients with an unfavorable clinical outcome are characterized by increased levels of coordinated MRP1 and MRP3 mRNA expression in their tumor samples. Furthermore, a higher level of MRP1 mRNA expression can be a candidate for a useful predictor of a shorter period of progression-free survival.